Taken together, this complexity of FAK action in cancer theoretically allows for different starting points for potential FAK-addressed anti-cancer strategies, i.e., (i) FAK expression per se, (ii) FAK translocation to the nucleus, and (iii) FAK kinase and scaffolding functions. The gene discussed is PTK2; the disease is cancer.